Department of Dermatology, UAB Skin Diseases Research Center and UAB Comprehensive Cancer Center, The University of Alabama at Birmingham, 35294-0019, USA.
Cancer Prev Res (Phila). 2010 Jan;3(1):8-11. doi: 10.1158/1940-6207.CAPR-09-0248.
Bailey et al. report in this issue of the journal (beginning on page 35) one of the first successful trials of basal cell carcinoma (BCC) prevention. Oral alpha-difluoromethyl-dl-ornithine (DFMO) reduced new BCCs in patients with a prior history of nonmelanoma skin cancer. DFMO is an inhibitor of ornithine decarboxylase, a key enzyme in the polyamine biosynthetic pathway. This perspective on Bailey et al. discusses our knowledge of the contribution of polyamines to BCC pathogenesis, how this knowledge advanced the development of a new method to prevent BCCs, and prospects for future studies of DFMO in BCC prevention.
贝利等人在本期杂志（第 35 页开始）报告了基底细胞癌（BCC）预防的首次成功试验之一。口服α-二氟甲基-dl-鸟氨酸（DFMO）可减少有非黑色素瘤皮肤癌既往史的患者新发生的 BCC。DFMO 是鸟氨酸脱羧酶的抑制剂，鸟氨酸脱羧酶是多胺生物合成途径中的关键酶。对贝利等人的这一观点进行了讨论，内容涉及多胺对 BCC 发病机制的作用、这方面的认识如何促进预防 BCC 的新方法的发展，以及 DFMO 预防 BCC 的未来研究前景。
